168 related articles for article (PubMed ID: 32314187)
1. Cisplatin and farnesol co-encapsulated PLGA nano-particles demonstrate enhanced anti-cancer potential against hepatocellular carcinoma cells in vitro.
Mondal J; Khuda-Bukhsh AR
Mol Biol Rep; 2020 May; 47(5):3615-3628. PubMed ID: 32314187
[TBL] [Abstract][Full Text] [Related]
2. Synergism of cisplatin-oleanolic acid co-loaded calcium carbonate nanoparticles on hepatocellular carcinoma cells for enhanced apoptosis and reduced hepatotoxicity.
Khan MW; Zhao P; Khan A; Raza F; Raza SM; Sarfraz M; Chen Y; Li M; Yang T; Ma X; Xiang G
Int J Nanomedicine; 2019; 14():3753-3771. PubMed ID: 31239661
[No Abstract] [Full Text] [Related]
3. Cisplatin and curcumin co-loaded nano-liposomes for the treatment of hepatocellular carcinoma.
Cheng Y; Zhao P; Wu S; Yang T; Chen Y; Zhang X; He C; Zheng C; Li K; Ma X; Xiang G
Int J Pharm; 2018 Jul; 545(1-2):261-273. PubMed ID: 29730175
[TBL] [Abstract][Full Text] [Related]
4. PLGA-encapsulated tea polyphenols enhance the chemotherapeutic efficacy of cisplatin against human cancer cells and mice bearing Ehrlich ascites carcinoma.
Singh M; Bhatnagar P; Mishra S; Kumar P; Shukla Y; Gupta KC
Int J Nanomedicine; 2015; 10():6789-809. PubMed ID: 26586942
[TBL] [Abstract][Full Text] [Related]
5. Co-delivery of cisplatin and paclitaxel by folic acid conjugated amphiphilic PEG-PLGA copolymer nanoparticles for the treatment of non-small lung cancer.
He Z; Huang J; Xu Y; Zhang X; Teng Y; Huang C; Wu Y; Zhang X; Zhang H; Sun W
Oncotarget; 2015 Dec; 6(39):42150-68. PubMed ID: 26517524
[TBL] [Abstract][Full Text] [Related]
6. Kanglaite enhances the efficacy of cisplatin in suppression of hepatocellular carcinoma via inhibiting CKLF1 mediated NF-κB pathway and regulating transporter mediated drug efflux.
Chen C; Ai QD; Wei YH
J Ethnopharmacol; 2021 Jan; 264():113388. PubMed ID: 32918990
[TBL] [Abstract][Full Text] [Related]
7. pH-sensitive polymeric nanoparticles for co-delivery of doxorubicin and curcumin to treat cancer via enhanced pro-apoptotic and anti-angiogenic activities.
Zhang J; Li J; Shi Z; Yang Y; Xie X; Lee SM; Wang Y; Leong KW; Chen M
Acta Biomater; 2017 Aug; 58():349-364. PubMed ID: 28455219
[TBL] [Abstract][Full Text] [Related]
8. Targeted hepatocellular carcinoma therapy: transferrin modified, self-assembled polymeric nanomedicine for co-delivery of cisplatin and doxorubicin.
Zhang X; Li J; Yan M
Drug Dev Ind Pharm; 2016 Oct; 42(10):1590-9. PubMed ID: 26942448
[TBL] [Abstract][Full Text] [Related]
9. Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib.
Zheng N; Liu W; Li B; Nie H; Liu J; Cheng Y; Wang J; Dong H; Jia L
J Exp Clin Cancer Res; 2019 May; 38(1):232. PubMed ID: 31151472
[TBL] [Abstract][Full Text] [Related]
10. Using acetaminophen's toxicity mechanism to enhance cisplatin efficacy in hepatocarcinoma and hepatoblastoma cell lines.
Neuwelt AJ; Wu YJ; Knap N; Losin M; Neuwelt EA; Pagel MA; Warmann S; Fuchs J; Czauderna P; Wozniak M
Neoplasia; 2009 Oct; 11(10):1003-11. PubMed ID: 19794959
[TBL] [Abstract][Full Text] [Related]
11. Lenvatinib and Cu
Xu Q; Li Q; Yang Z; Huang P; Hu H; Mo Z; Qin Z; Xu Z; Chen T; Yang S
J Mater Chem B; 2021 Dec; 9(48):9908-9922. PubMed ID: 34842266
[TBL] [Abstract][Full Text] [Related]
12. Synergy of Raddeanin A and cisplatin induced therapeutic effect enhancement in human hepatocellular carcinoma.
Li JN; Yu Y; Zhang YF; Li ZM; Cai GZ; Gong JY
Biochem Biophys Res Commun; 2017 Apr; 485(2):335-341. PubMed ID: 28219642
[TBL] [Abstract][Full Text] [Related]
13. The role of a drug-loaded poly (lactic co-glycolic acid) (PLGA) copolymer stent in the treatment of ovarian cancer.
Wang Y; Qiao X; Yang X; Yuan M; Xian S; Zhang L; Yang D; Liu S; Dai F; Tan Z; Cheng Y
Cancer Biol Med; 2020 Feb; 17(1):237-250. PubMed ID: 32296591
[No Abstract] [Full Text] [Related]
14. Vasohibin 2 decreases the cisplatin sensitivity of hepatocarcinoma cell line by downregulating p53.
Li Z; Tu M; Han B; Gu Y; Xue X; Sun J; Ge Q; Miao Y; Qian Z; Gao W
PLoS One; 2014; 9(3):e90358. PubMed ID: 24595063
[TBL] [Abstract][Full Text] [Related]
15. Improved drug carriage and protective potential against Cisplatin-induced toxicity using Boldine-loaded PLGA nanoparticles.
Mondal J; Patra M; Panigrahi AK; Khuda-Bukhsh AR
J Ayurveda Integr Med; 2020; 11(1):24-36. PubMed ID: 30115410
[TBL] [Abstract][Full Text] [Related]
16. Novel combinational treatment of cisplatin with cyclophilin A inhibitors in human heptocellular carcinomas.
Lee J
Arch Pharm Res; 2010 Sep; 33(9):1401-9. PubMed ID: 20945139
[TBL] [Abstract][Full Text] [Related]
17. Neferine and isoliensinine enhance 'intracellular uptake of cisplatin' and induce 'ROS-mediated apoptosis' in colorectal cancer cells - A comparative study.
Manogaran P; Beeraka NM; Huang CY; Vijaya Padma V
Food Chem Toxicol; 2019 Oct; 132():110652. PubMed ID: 31255669
[TBL] [Abstract][Full Text] [Related]
18. 5-Fluorouracil combined with apigenin enhances anticancer activity through mitochondrial membrane potential (ΔΨm)-mediated apoptosis in hepatocellular carcinoma.
Hu XY; Liang JY; Guo XJ; Liu L; Guo YB
Clin Exp Pharmacol Physiol; 2015 Feb; 42(2):146-53. PubMed ID: 25363523
[TBL] [Abstract][Full Text] [Related]
19. Apoptosis-inducing activity of cisplatin (CDDP) against human hepatoma and oral squamous cell carcinoma cell lines.
Okamura M; Hashimoto K; Shimada J; Sakagami H
Anticancer Res; 2004; 24(2B):655-61. PubMed ID: 15161008
[TBL] [Abstract][Full Text] [Related]
20. Improved antitumor activity and reduced cardiotoxicity of epirubicin using hepatocyte-targeted nanoparticles combined with tocotrienols against hepatocellular carcinoma in mice.
Nasr M; Nafee N; Saad H; Kazem A
Eur J Pharm Biopharm; 2014 Sep; 88(1):216-25. PubMed ID: 24813390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
